Goldman Sachs analyst Rajan Sharma upgraded Genmab A/S (NASDAQ: GMAB) from Neutral to Buy with a price target of $30.50 (from $24.50).

For an analyst ratings summary and ratings history on Genmab A/S click here. For more ratings news on Genmab A/S click here.

Shares of Genmab A/S closed at $27.06 yesterday.